Skoči na glavni sadržaj

Psychiatria Danubina, Vol. 31 No. suppl 3, 2019.

Izlaganje sa skupa

EFFICACY OF KETAMINE IN BIPOLAR DEPRESSION: FOCUS ON ANHEDONIA

Maria Gałuszko-Węgielnik ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Mariusz Stanisław Wiglusz ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Jakub Słupski ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Łukasz Szałach ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Adam Włodarczk ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Natalia Górska ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Joanna Szarmach ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Katarzyna Jakuszkowiak-Wojten ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Alina Wilkowska ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Wiesław Jerzy Cubała ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

Puni tekst: engleski pdf 411 Kb

str. 554-560

preuzimanja: 404

citiraj

Sažetak

Bipolar depression (BD) is among the most severe psychiatric disorders. A significant number of patients do not achieve an
entirely symptom-free state and experience residual sub-syndromal depression. Most of the treatment options approved for bipolar
depression give no rapid symptom improvement. Ketamine is an anaesthetic medication that acts as an antagonist of the NMDA
receptor and has antidepressant potential. Due to its unique way of action, ketamine seems to be crucial for the treatment of
anhedonia. This review paper aims to provide an overview of the efficacy of ketamine infusions in bipolar depression with a focus on
anhedonia Literature suggests that intravenous ketamine 0.5 mg/kg over 40min weekly could be useful in the treatment of bipolar
depression with prominent anhedonia, but there is still a small number of studies that examine the efficacy of ketamine infusions in
BD. In conclusion, ketamine should be considered as a valuable treatment option for patients with BD and anhedonia.

Ključne riječi

ketamine; Bipolar depression; anhedonia

Hrčak ID:

264172

URI

https://hrcak.srce.hr/264172

Datum izdavanja:

4.9.2019.

Posjeta: 540 *